Zumandimine(Ethinyl Estradiol/Drospirenone)
AUROPHARMA.NS
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Aurobindo Pharma Limited
$8,364
Medicare cost, 2024
$8,364
Medicare cost, 2024
Medicare drug plans spent $8,364 on Zumandimine (ethinyl estradiol/drospirenone) in 2024, for 222 prescriptions and refills filled by 94 patients. New York accounts for the most spending ($1,042, 12% of the total). It is made by Aurobindo Pharma Limited (AUROPHARMA.NS).
Medicare cost, 2024
$8,364
+0.1% from 2023
Prescriptions
222
$37.67 per claim
Patients
94
98 prescribers
Total spending, 2024
$8,364
$88.98 per patient
Questions and answers
How much does Medicare spend on Zumandimine?
Medicare prescription drug plans paid $8,364 for Zumandimine in 2024, for 222 prescriptions and refills to 94 patients (up 0.1% from 2023). The average cost per claim was $37.67.
Which state spends the most on Zumandimine?
New York had the highest Medicare cost for Zumandimine in 2024: $1,042 for 19 claims, followed by Colorado ($1,021).
Who prescribes Zumandimine the most?
Laurie Miller, family practice in Fort Collins, CO, had the highest Medicare cost for Zumandimine in 2024: 11 claims costing $623.
Who makes Zumandimine?
Zumandimine is made by Aurobindo Pharma Limited (AUROPHARMA.NS), listed in the Medicare spending data as Aurobindo Pharm.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Zumandimine was $8,364 in 2024, after a high of $27K in 2021.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Zumandimine, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Laurie Miller Fort Collins, CO | Family Practice | 11 | Under 11 | $623 |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 152 | 468 | 139 | $21K |
| 2023 | 67 | 241 | 64 | $8,352 |
| 2024 | 98 | 222 | 94 | $8,364 |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Aurobindo Pharm | 222 | $8,364 |
Medicaid spending by quarter
Amount reimbursed by state Medicaid programs, all states
Amount reimbursed
Codes
- National drug codes (packages)
- 4
- RxNorm concept IDs
- 2045196, 284207, 748797, 748800
- Application numbers
- ANDA209407
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 44,024 side-effect reports named drospirenone and ethinyl estradiol, the active ingredient of Zumandimine (reports from 2004 on). 34,495 of them (78.4%) were serious, 668 named a death and 20,304 named a hospital stay. The reactions named most often were pain, injury and pulmonary embolism. 1,602 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
44,024
297 in 2025 (-1.7% from 2024)
Serious
78.4%
34,495 reports
Deaths named
668
1.5% of reports
Hospital stays
20,304
46.1% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Zumandimine?
44,024 reports from 2004 through September 2026 named drospirenone and ethinyl estradiol, the active ingredient of Zumandimine. 34,495 of them (78.4%) were serious, 668 named a death and 20,304 named a hospital stay.
What are the most reported side effects of Zumandimine?
12,874 reports named pain, the reaction named most often, followed by injury (10,713) and pulmonary embolism (9,177). In the last 5 years the reaction named most often was off label use (155 reports). A report can name several reactions.
How many side-effect reports named Zumandimine in 2025?
297 reports were received in 2025 (-1.7% from 2024). 2026 so far: 256 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Zumandimine caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Zumandimine caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Other Medicare drug pages with drospirenone and ethinyl estradiol: Nikki, Syeda, Yaz, Lo-Zumandimine, Vestura, Jasmiel
- Makers on the stock market:
AUROPHARMA.NS
BAYN.DE
LUPIN.NS
TEVA·AUROPHARMA.NS drug pipeline - Drug approvals (6 approvals on file for drospirenone and ethinyl estradiol) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (drospirenone and ethinyl estradiol) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.